Medicine and Dentistry
Patient
100%
Therapeutic Procedure
100%
Combination Therapy
83%
Ribavirin
66%
Peginterferon
66%
Telaprevir
50%
Anemia
33%
Virus RNA
33%
Adverse Event
33%
Hepatitis C Virus
33%
Exanthem
33%
Treatment Response
16%
Fibrosis
16%
Recurrent Disease
16%
Chronic Hepatitis C
16%
Liver Cirrhosis
16%
Treatment Duration
16%
Monitoring
16%
Clinical Significance
16%
Nursing and Health Professions
Combination Therapy
83%
Ribavirin
66%
Peginterferon
66%
Length
50%
Telaprevir
50%
Adverse Event
33%
Anemia
33%
Virus RNA
33%
Rash
33%
Fibrosis
16%
Liver Cirrhosis
16%
Treatment Duration
16%
Gold Standard
16%
Recurrent Disease
16%
Treatment Response
16%
Chronic Hepatitis C
16%
Dose
16%
Monitoring
16%
Sustained Virologic Response
16%
Pharmacology, Toxicology and Pharmaceutical Science
Peginterferon
66%
Ribavirin
66%
Telaprevir
50%
Adverse Event
33%
Hepatitis C Virus
33%
Anemia
33%
Rash
33%
Chronic Hepatitis C
16%
Recurrent Disease
16%
Combination Therapy
16%
Fibrosis
16%
Liver Cirrhosis
16%
Neuroscience
Ribavirin
66%
Pegylated Interferon
66%
Hepatitis C Virus
50%
Telaprevir
50%
Adverse Effect
33%
Sustained Viral Response
16%
Biochemistry, Genetics and Molecular Biology
Hepatitis C Virus
50%
Length
50%
RNA Virus
33%
Reduction (Chemistry)
16%
Dose
16%